Publications by authors named "Y Kawa"
Article Synopsis
- RUNX2 is a key transcription factor for bone formation, and its activity is crucially controlled by the levels of expression, as shown by studies in mutant mice with skeletal abnormalities.
- This research focused on using CRISPR-based epigenome editing to induce hypermethylation in a specific region (Runx2-DMR) to assess its impact on RUNX2 expression during the differentiation of bone-forming cells (osteoblasts).
- The findings indicated that while hypermethylation successfully reduced Runx2 expression, it did not alter the expression of downstream target genes, revealing that DNA methylation at the Runx2-DMR is dynamically regulated during the differentiation process.
Background: Pembrolizumab plus epacadostat (indoleamine 2,3-dioxygenase-1 inhibitor) was well tolerated in Japanese patients with advanced solid tumors in part A of the nonrandomized, open-label, phase 1 KEYNOTE-434 study (NCT02862457). We report results from part B, which evaluated epacadostat plus pembrolizumab and chemotherapy in Japanese patients with advanced non-small-cell lung cancer (NSCLC).
Methods: Eligible patients aged ≥ 20 years had histologically or cytologically confirmed stage IIIB or IV NSCLC with no prior systemic therapy, and ECOG performance status of 0 or 1.
Objectives: The combination of chemotherapy and immune checkpoint inhibitors (chemo-ICI) has become the new standard of treatment for extensive-stage small cell lung cancer (ES-SCLC). Recently, slight changes in interstitial shadows, defined as interstitial lung abnormalities (ILA), have been identified. In patients with ES-SCLC who received chemo-ICI, there are limited data on the incidence of drug-induced interstitial lung disease (D-ILD) in daily practice and the association between the development of D-ILD and ILA in the baseline computed tomography (CT).
View Article and Find Full Text PDFA patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib.
View Article and Find Full Text PDFPurpose: This study aimed to determine the incidence and clinical course of epidermal growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT).
Patients And Methods: We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-mutated lung cancer who received EGFR-tyrosine kinase inhibitors (TKIs) between 2012 and 2019. The primary outcome was the incidence of HT.